MedTech Unboxed: Christopher Haig, President at Efemoral Medical
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
MedTech Unboxed: Christopher Haig, President at Efemoral Medical
-
Narrated by:
-
By:
About this listen
A new MedTech Unboxed episode is out now with Christopher Haig, President of Efemoral Medical, a company developing bioresorbable scaffolds for treating peripheral arterial disease (PAD), affecting over 200 million globally. Here’s a snapshot of our discussion:
- FlexStep Technology: A balloon-expandable, drug-eluting bioresorbable scaffold with inter-scaffold spaces for flexibility, made of PLLA with a co-polymer for ductility and rapid resorption (1-2 years), eluting sirolimus to prevent restenosis.
- Clinical Progress: The EFEMORAL I trial (33 patients enrolled across 4 sites in New Zealand/Australia) shows promise, with 20-patient results to be presented by Dr. Andrew Holden at @CXSymposium in London, April 23, 2025.
- Funding Update: Raised $10M+ in equity through angel investors and $2M+ in SBIR grants; targeting $20M Series B for IDE submission, including GLP animal studies and randomized trials for US PMA approval.
What listeners say about MedTech Unboxed: Christopher Haig, President at Efemoral Medical
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.